Back

Clinical Relevant Immunosuppressive Drugs Differentially Modulate Axonal Outgrowth from Human Stem Cell Derived Neurons

Poplawski, G. H. D.; Weinholtz, C.; Woodruff, G.; Ahmad, R.; Bunner, W.; Gonzales, R.; Tuszynski, M. H.

2026-07-03 neuroscience
10.64898/2026.06.29.735084 bioRxiv
Show abstract

Neural stem cell (NSC) transplantation is a promising strategy for repairing the injured spinal cord, but transplanted cells typically require immunosuppressive therapy to prevent rejection, even for induced pluripotent stem cell (iPSC)-derived autologous grafts. However, the effects of immunosuppressive drugs on neurite outgrowth and axonal regeneration, processes critical for neural circuit reconstruction, have not been fully characterized. In this study, we tested nine clinically relevant immunosuppressants on human iPSC-derived neurons and primary human spinal cord NSCs in vitro at concentrations approximating clinical exposure levels. The drug panel included FK-506 (tacrolimus), cyclosporine A (CsA), rapamycin, belatacept (Nulojix), etanercept (Enbrel), mycophenolate mofetil (CellCept), cyclophosphamide (Cytoxan), prednisone, and azathioprine (Imuran). Neurite outgrowth was quantified via automated high-content imaging. Multiple agents, including CsA, Imuran, Nulojix, and CellCept, induced significant reductions in neurite outgrowth in a cell type- and dose-dependent manner, with CsA producing the most robust and consistent inhibition across both cell lines. In contrast, FK-506 showed no significant effect on neurite extension at clinically relevant concentrations. Consistent with the in vitro results, human neural progenitor cell grafts in a rodent spinal cord injury model exhibited significantly reduced graft-derived axon extension in the host spinal cord when hosts were treated with CsA rather than FK-506. These findings demonstrate that immunosuppressant choice can profoundly influence neural graft integration and axonal regeneration. Our study underscores the importance of preclinical evaluation of immunosuppressive regimens and suggests that selecting agents such as FK-506 over CsA may improve outcomes in future stem cell-based therapeutic trials for spinal cord injury and related disorders of the central nervous system.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Frontiers in Cellular Neuroscience
91 papers in training set
Top 0.1%
6.9%
2
Scientific Reports
3612 papers in training set
Top 12%
6.4%
3
JCI Insight
277 papers in training set
Top 0.8%
6.4%
4
PLOS ONE
5266 papers in training set
Top 27%
5.7%
5
Journal of Neuroscience Methods
122 papers in training set
Top 0.4%
5.0%
6
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.2%
4.4%
7
Experimental Neurology
61 papers in training set
Top 0.3%
4.1%
8
Frontiers in Molecular Neuroscience
47 papers in training set
Top 0.1%
4.1%
9
Journal of Neurochemistry
53 papers in training set
Top 0.3%
2.7%
10
Brain Research
38 papers in training set
Top 0.1%
2.5%
11
Cells
249 papers in training set
Top 2%
2.5%
50% of probability mass above
12
Stem Cell Reports
130 papers in training set
Top 0.9%
2.5%
13
Journal of Neurotrauma
31 papers in training set
Top 0.3%
1.7%
14
Communications Biology
993 papers in training set
Top 16%
1.5%
15
eneuro
439 papers in training set
Top 5%
1.4%
16
Stem Cell Research & Therapy
30 papers in training set
Top 0.4%
1.4%
17
ACS Chemical Neuroscience
67 papers in training set
Top 0.9%
1.4%
18
Molecular Medicine
11 papers in training set
Top 0.2%
1.2%
19
International Journal of Molecular Sciences
494 papers in training set
Top 10%
1.2%
20
eLife
5828 papers in training set
Top 59%
1.1%
21
Cell Reports
1498 papers in training set
Top 25%
1.0%
22
Science Translational Medicine
127 papers in training set
Top 3%
0.9%
23
Muscle & Nerve
10 papers in training set
Top 0.3%
0.9%
24
ASN Neuro
10 papers in training set
Top 0.1%
0.9%
25
Stem Cells
31 papers in training set
Top 0.6%
0.9%
26
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 2%
0.9%
27
The FASEB Journal
194 papers in training set
Top 5%
0.9%
28
Cancers
213 papers in training set
Top 5%
0.6%
29
Advanced Biology
29 papers in training set
Top 0.9%
0.6%
30
Neuroscience
97 papers in training set
Top 2%
0.6%